Improving Care Pathways for Acute Coronary Syndrome: Patients Undergoing Percutaneous Coronary Intervention
Affiliations
- PMID: 31812224
- DOI: 10.1016/j.amjcard.2019.10.019
Abstract
Acute coronary syndrome (ACS) admissions are common and costly. The association between comprehensive ACS care pathways, outcomes, and costs are lacking. From 434,172 low-risk, uncomplicated ACS patients eligible for early discharge (STEMI 35%, UA/NSTEMI 65%) from the Premier database, we identified ACS care pathways, by stratifying low-risk, uncomplicated STEMI and UA/NSTEMI patients by access site for PCI (trans-radial intervention [TRI] vs transfemoral intervention [TFI]) and by length of stay (LOS). Associations with costs and outcomes (death, bleeding, acute kidney injury, and myocardial infarction at 1-year) were tested using hierarchical, mixed-effects regression, and projections of cost savings with change in care pathways were obtained using modeling. In low-risk uncomplicated STEMI patients, compared with TFI and LOS ≥3 days, a strategy of TRI with LOS <3 days and TFI with LOS <3 days were associated with cost savings of $6,206 and $4,802, respectively. Corresponding cost savings for UA/NSTEMI patients were $7,475 and $6,169, respectively. These care-pathways did not show an excess risk of adverse outcomes. We estimated that >$300 million could be saved if prevalence of the TRI with LOS <3 days and TFI with LOS <3 days strategies are modestly increased to 20% and 70%, respectively. In conclusion, we demonstrate the potential opportunity of cost savings by repositioning ACS care pathways in low-risk and uncomplicated ACS patients, toward transradial access and a shorter LOS without an increased risk of adverse outcomes.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
- Costs of transradial percutaneous coronary intervention.JACC Cardiovasc Interv. 2013 Aug;6(8):827-34. doi: 10.1016/j.jcin.2013.04.014. Epub 2013 Jul 17.PMID: 23871512 Clinical Trial.
- Costs of payment in Thai acute coronary syndrome patients.J Med Assoc Thai. 2007 Oct;90 Suppl 1:21-31.PMID: 18431883 Clinical Trial.
- Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States.JACC Cardiovasc Interv. 2017 Feb 27;10(4):342-351. doi: 10.1016/j.jcin.2016.11.049.PMID: 28231901 Clinical Trial.
- Transradial versus transfemoral percutaneous coronary intervention in acute coronary syndromes: re-evaluation of the current body of evidence.JACC Cardiovasc Interv. 2013 Nov;6(11):1149-52. doi: 10.1016/j.jcin.2013.08.003.PMID: 24262614 Review.
- Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290.PMID: 25896573 Free PMC article. Review.
No hay comentarios:
Publicar un comentario